Search results for "Acitretin"

showing 8 items of 8 documents

2019

These days, the important role of retinoids in adult brain functionality and homeostasis is well accepted and has been proven by genomic as well as non-genomic mechanisms. In the healthy brain, numerous biological processes, e.g., cell proliferation, neurogenesis, dendritic spine formation as well as modulation of the immune system, have been attributed to retinoid signaling. This, together with the finding that retinoid metabolism is impaired in Alzheimer's disease (AD), led to preclinical and early clinical testing of natural and synthetic retinoids as innovative pharmaceuticals with multifactorial properties. Acitretin, an aromatic retinoid, was found to exert an anti-amyloidogenic effec…

0301 basic medicineAgingmedicine.drug_classbusiness.industryCognitive NeuroscienceNeurogenesisCentral nervous systemRetinoic acidPharmacologymedicine.diseaseBlood–brain barrierAcitretin03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicineImmune systemmedicine.anatomical_structurechemistrymedicineRetinoidAlzheimer's diseasebusiness030217 neurology & neurosurgerymedicine.drugFrontiers in Aging Neuroscience
researchProduct

Rescue of Hypovitaminosis A Induces Non-Amyloidogenic Amyloid Precursor Protein (APP) Processing.

2015

Retinoic acid, the bioactive metabolite of beta-carotene or vitamin A, plays a pleiotropic, multifunctional role in vertebrate development. Studies in rodents revealed that a diet deficient in vitamin A results in a complex neonatal syndrome (the VAD syndrome), manifested in many organs. In humans, the function of retinoic acid (RA) extends into adulthood, where it has important roles in fertility, vision, and suppression of neoplastic growth. In recent years, it has also been suggested that retinoic acid might potentially act as a therapeutically relevant drug in attenuating or even preventing neurodegenerative diseases such as Alzheimer's disease (AD). Here, we report that VAD leads to an…

0301 basic medicineVitaminmedicine.medical_specialtyADAM10Retinoic acidTretinoin03 medical and health scienceschemistry.chemical_compoundADAM10 ProteinAmyloid beta-Protein PrecursorMiceNeuroblastoma0302 clinical medicineKeratolytic AgentsTretinoinInternal medicineNeuroblastomaGene expressionPresenilin-2medicineAmyloid precursor proteinAnimalsHumansGene Regulatory NetworksRats WistarCells CulturedCerebral CortexNeuronsAmyloid beta-PeptidesbiologyVitamin A Deficiencymedicine.diseaseAcitretinPeptide FragmentsVitamin A deficiencyDisease Models Animal030104 developmental biologyEndocrinologyNeurologychemistryAnimals Newbornbiology.proteinFemaleNeurology (clinical)030217 neurology & neurosurgerymedicine.drugCurrent Alzheimer research
researchProduct

Retinoids and proliferative verrucous leukoplakia (PVL). A preliminary study.

2010

Objective. A study is made of the efficacy and adverse effects of retinoid therapy applied to the white lesions of proliferative verrucous leukoplakia (PVL). Material and methods. The results of retinoid therapy were evaluated in 17 patients diagnosed with PVL. Topical retinoids were used in 5 patients, in the form of two daily applications of 0.1% 13-cis-retinoic acid in orabase for an average of 6.17+/-3.13 months. Systemic retinoids were used in 11 patients, with the administration of 25 mg/day of acitretin in tablet form for an average of 5.41+/-2.02 months. One patient successively received the topical and systemic retinoid formulations. The course and results were evaluated on a blind…

AdultMalemedicine.medical_specialtymedicine.drug_classSystemic therapyAcitretinDesquamationLesionRetinoidsOral and maxillofacial pathologymedicineHumansRetinoidAdverse effectGeneral DentistryLeukoplakiaAgedAged 80 and overbusiness.industryMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]DermatologyOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryFemalemedicine.symptomLeukoplakia Oralbusinessmedicine.drugMedicina oral, patologia oral y cirugia bucal
researchProduct

Keratoacanthoma Centrifugum Marginatum (KCM) after photodynamic therapy with good response to oral retinoids and topical 5‐fluorouracil

2019

Keratoacanthoma centrifugum marginatum (KCM) is a rare variant of keratoacanthoma (KA), characterized by progressive peripheral growth, and usually devoid of deep invasion. Different systemic (oral retinoids) or topical treatments have been reported, but there is not a well-defined therapeutic protocol. We report the case of a KCM developing after photodynamic therapy (PDT) on the right leg of a 64-year-old woman. It was treated successfully with oral acitretin combined with topical 5-Fluorouracil + salicylic acid for 5 months. This is the first case of KCM developing after PDT and successfully treated with oral retinoid combined with topical treatment.

Keratoacanthomamedicine.medical_specialtymedicine.medical_treatmentAdministration OralTopical treatmentPhotodynamic therapyDermatologyAdministration CutaneousAcitretinRetinoids030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinemedicineHumansbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseDermatologyAcitretinKeratoacanthomaTreatment OutcomePhotochemotherapyFluorouracil030220 oncology & carcinogenesisFemaleDermatologic AgentsFluorouracilbusinessOral retinoidmedicine.drugDermatologic Therapy
researchProduct

Increased CSF APPs-  levels in patients with Alzheimer disease treated with acitretin

2014

Objective: We investigated induction of α-secretase A disintegrin and metalloprotease 10 (ADAM10) by the synthetic retinoid acitretin (Neotigason; Actavis, Munchen-Riem, Germany) in patients with mild to moderate Alzheimer disease (AD) via measurement of CSF content of α-secretase–derived amyloid precursor protein (APPs-α). Methods: Twenty-one patients clinically diagnosed with mild to moderate AD received acitretin (30 mg per day) or placebo in a 4-week double-blind study. Primary endpoint was the difference of CSF APPs-α ratios calculated from the APPs-α levels after treatment and at baseline. We monitored safety and tolerability of the treatment. In addition, we assessed biomarkers such …

MaleDrugmedicine.medical_specialtymedia_common.quotation_subjectPilot ProjectsPlaceboGastroenterologyAcitretinlaw.inventionDouble-Blind MethodRandomized controlled trialAlzheimer Diseasecerebrospinal fluid [Amyloid Precursor Protein Secretases]lawInternal medicinemedicineClinical endpointdrug therapy [Alzheimer Disease]Humansddc:610Prospective StudiesProspective cohort studyAgedmedia_commonbusiness.industrytherapeutic use [Acitretin]diagnosis [Alzheimer Disease]Middle Agedmedicine.diseaseAcitretincerebrospinal fluid [Alzheimer Disease]Treatment Outcomecerebrospinal fluid [Biomarkers]TolerabilityFemaleNeurology (clinical)Amyloid Precursor Protein SecretasesAlzheimer's diseasebusinessBiomarkersmedicine.drugNeurology
researchProduct

Acitretin, an Enhancer of Alpha-Secretase Expression, Crosses the Blood-Brain Barrier and Is Not Eliminated by P-Glycoprotein

2011

<i>Background:</i> ADAM10 (a disintegrin and metalloproteinase 10) has been demonstrated to act as the main physiological α-secretase. Enzymatic activity of the α-secretase on the one hand prevents the formation of toxic Aβ peptides and on the other hand promotes the secretion of a neurotrophic and neuroprotective amyloid precursor protein fragment (APPs-α) by cleaving the amyloid precursor protein within its Aβ sequence. Enhancement of ADAM10’s gene expression may therefore present a valuable therapeutic approach for the treatment of Alzheimer’s disease (AD), where Aβ peptides are severely involved in the pathogenesis. <i>Objective:</i> In cell culture and in a tran…

MaleGenetically modified mouseATP Binding Cassette Transporter Subfamily BTime FactorsADAM10PharmacologyTransfectionAcitretinADAM10 ProteinMiceNeuroblastomachemistry.chemical_compoundCell Line TumormedicineAmyloid precursor proteinAnimalsHumansATP Binding Cassette Transporter Subfamily B Member 1Chromatography High Pressure LiquidP-glycoproteinMice KnockoutAnalysis of VarianceReporter genebiologyMembrane ProteinsMolecular biologyAcitretinADAM ProteinsGene Expression RegulationNeurologychemistryAlpha secretaseBlood-Brain Barrierbiology.proteinTamibaroteneNeurology (clinical)Amyloid Precursor Protein Secretasesmedicine.drugNeurodegenerative Diseases
researchProduct

Up‐regulation of the α‐secretase ADAM10 by retinoic acid receptors and acitretin

2009

Late-onset Alzheimer's disease is often connected with nutritional misbalance, such as enhanced cholesterol intake, deficiency in polyunsaturated fatty acids, or hypovitaminosis. The alpha-secretase ADAM10 has been found to be regulated by retinoic acid, the bioreactive metabolite of vitamin A. Here we show that retinoids induce gene expression of ADAM10 and alpha-secretase activity by nonpermissive retinoid acid receptor/retinoid X receptor (RAR/RXR) heterodimers, whereby alpha- and beta-isotypes of RAR play a major role. However, ligands of other RXR binding partners, such as the vitamin D receptor, do not stimulate alpha-secretase activity. On the basis of these findings, we examined the…

Malemedicine.medical_specialtyReceptors Retinoic AcidReceptors Cytoplasmic and NuclearMice TransgenicTretinoinRetinoic acid receptor betaRetinoid X receptorBiologyBiochemistryCell LineAcitretinADAM10 ProteinAmyloid beta-Protein PrecursorMiceKeratolytic AgentsAlzheimer DiseaseInternal medicineGeneticsmedicineAnimalsHumansPromoter Regions GeneticMolecular BiologyLiver X ReceptorsReceptors Thyroid HormoneMolecular StructureRetinoid X receptor alphaMembrane ProteinsOrphan Nuclear ReceptorsRetinoid X receptor gammaAcitretinUp-RegulationDNA-Binding ProteinsPPAR gammaADAM ProteinsRetinoic acid receptorRetinoid X ReceptorsEndocrinologyGene Expression RegulationRetinoic acid receptor alphaReceptors CalcitriolAmyloid Precursor Protein SecretasesRetinoid X receptor betaBiotechnologymedicine.drugThe FASEB Journal
researchProduct

Severe nail psoriasis with a rapid response to acitretin

2009

medicine.medical_specialtybusiness.industrymedicineDermatologybusinessNail psoriasisDermatologyRapid responseAcitretinmedicine.drugClinical and Experimental Dermatology
researchProduct